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serum interferon levels in mice treated with SSM, an
immunotherapeutic anticancer agent
F. Suzuki" 2, R.R. Brutkiewicz2 & R.B. Pollard2
'Division ofInfectious Diseases, Department ofInternal Medicine and Department ofMicrobiology,
University of Texas Medical Branch, Virology Division, Shriners Burns Institute, Galveston, Texas
77550, USA; and 2Department ofMicrobiology, Kumamoto University Medical School, Kumamoto 860,
Japan.
Many immunomodulators induce the production of
interferons (IFN) in vivo (Matsubara et al., 1981)
and exhibit antitumour activities in animals and
patients with cancer (Mastrangelo et al., 1981). The
antitumour effect of IFN have been also demon-
strated in experimental models and in various
human tumours (Sikora et al., 1983). These
immunomodulators, as well as IFN, have been
reported to increase natural killer (NK) cell
activity, cytotoxic T-cell (CTL) activity, and
macrophage (Mq)-mediated tumour cell killing
(Mastrangelo et al., 1981). Despite a correlation
between the in vivo antitumour activity of the
agents and the ability to stimulate IFN production,
exceptions have been reported (Weinstein et al.,
1971). SSM, an arabinomannanlipid preparation
extracted from cultured cells of Mycobacterium
tuberculosis strain Aoyama B (Kobatake et al.,
1981), is an immunopotentiating agent with IFN-
inducing (Hayashi et al., 1981) and antitumour
activity (Satoh, 1978; Kimoto, 1982). The IFN
induced by SSM has been shown to be gamma IFN
(IFNy) (Hayashi et al., 1981). Since SSM did not
display direct cytotoxicity against cancer cells when
they were cultured with the agent (Kimoto, 1982),
the antitumour effect of the agent might be
expressed through host defence functions. In the
present study, the role of SSM-induced circulating
IFNy in the antitumour activity of the agent was
investigated utilizing models of immuno-
compromised mice incapable of IFN production.
The in vivo strain of the BALB/c syngeneic
leukaemia, RLS1, was a gift from Dr J.Y. Djeu,
Division of Virology, Bureau of Biologics, FDA,
Bethesda, MD, USA. Ehrlich carcinoma cells
adapted to mice from an in vitro strain, were
obtained from the Department of Microbiology,
University of Texas Medical Branch, Galveston,
TX, USA. These tumours were maintained by serial
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passage in vivo by injecting 1-5 x 106 cells per
mouse, i.p., in BALB/c mice. The SSM (lot No. 123,
C-1) (Kobatake et al., 1981) was kindly supplied by
the Zeria Pharmaceutical Co., Ltd., Tokyo, Japan.
SSM (5-500pgkg-1, i.p.) or saline (0.5ml, i.p.) was
administered one day before and one day after
tumour inoculation, and was subsequently
continued every other day for a total of 10
treatments. Two kinds of immunocompromised
animals were used in this study: (i) Mice treated
with anti-mouse IFNy antiserum which was
prepared in rabbits immunized with staphylococcal
enterotoxin A (SEA)-induced IFNy. This material
has been shown to preferentially inactivate the
antiviral activity of IFNy in vitro while not reacting
with IFNoa or IFN,B (Osborne et al., 1980). Since
5mgkg-' of SSM administered i.v. to mice has
been reported to result in peak IFNy titers of
320Uml-1 in the circulation (Hayashi et al., 1981),
a dose of this antiserum capable of neutralizing
2,500Ukg-1 of IFN was given s.c. to mice
immediately after administering SSM. (ii)
Congenitally athymic nude (nu/nu) mice homo-
zygous for the recessive gene (nu), which were
severely limited in thymus-derived lymphocytes.
These animals are deficient in Thy 1 + T
lymphocytes (Pantelouris, 1968) which have been
shown to produce IFNy (Sonnenfeld et al., 1979).
As a positive control, normal BALB/c mice were
stimulated with SSM to induce IFN. Although
haired littermates of the nude mice are hetero-
zygous at the nu gene locus (nu/+), their T cell
functions have been reported to be intact
(Pantelouris, 1971). These nu/+ mice also served as
positive controls. After inoculation of the tumour
cells, mice were observed daily until day 50, and the
percent survival was calculated from the number of
mice which survived more than 50 days after
tumour inoculation. For the determination of
circulating IFN, blood samples were obtained from
various mice at appropriate intervals after the
injection of SSM. The blood samples were kept at
4°C overnight, then centrifuged at 1,250g for
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30min, and obtained serum specimens were assayed
for IFN on L-Galveston cells in a microplaque
reduction assay as described previously (Suzuki &
Pollard, 1982). To determine the dose response
effect of SSM on IFN induction in various mice,
sera were harvested 20h after various doses of SSM
administration. IFN levels were expressed as inter-
national Uml- 1 as compared to the standard
murine IFN (G-002-904-511). One U of the
experimental IFN samples was equivalent to 1.2U
of the international standard.
As shown in Figure 1, although normal and
nu/+ mice treated i.p. with 2.5mgkg-' of SSM
had IFN in the circulation which peaked 20h after
SSM administration, normal mice treated with
anti-mouse IFNy antiserum and nu/nu mice
stimulated with the same concentration of SSM had
no detectable serum IFN activity at any of the time
intervals examined. The impaired IFNy
responsiveness in immunocompromised mice treated
with SSM was also observed following the adminis-
tration of various concentrations of SSM. Sera were
harvested 20h after SSM injection and assayed. As
shown in Figure 2, while doses of SSM
>170pgkg-1 induced circulating IFN in normal
and nu/+ mice, no IFN was detected in mice
treated with anti-mouse IFNy antiserum or nu/nu
mice at any concentration used. This suggests that
the ability to produce circulating IFN following
stimulation with SSM was lacking in immuno-
compromised mice. Following determination of the
IFN-inducing activity of SSM in normal mice,
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Figure 1 Interferon induction by SSM in normal and
immunocompromised mice. Groups of 5 mice each (all
of the BALB/c background) received one i.p. injection
of 2.5mgkg-1 of SSM and the sera obtained at 4h
intervals were assayed for IFN. The groups of mice
utilized were as follows: mice treated with anti-mouse
IFNy antiserum (s.c., 2,500 neutralizing Ukg-1,
administered immediately after SSM treatment (-A-),
nu/+ mice (-A-), nu/nu mice (---), and normal
BALB/c mice (-O-). The IFN titers were determined
by the average obtained from 5 mice in each group.
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Figure 2 Effect of various concentrations of SSM on
IFN induction in normal and immunocompromised
mice. Five mice each (all of the BALB/c background)
were treated i.p. with various concentrations of SSM
(5-2,500pgkg-1). Sera from normal (-O-), nu/nu
(-U-), nu/+ (-A-), or normal mice treated with anti-
mouse IFNy antiserum as described above (-A-), were
obtained from the mice 20h after SSM administration
and assayed for antiviral activity.
heterozygous littermates of nude mice and two
kinds of immunocompromised mice, the antitumour
activity of SSM in these groups of mice was
investigated. As shown in Table Ta, significant
antitumour activity was olterved in normal mice
bearing Ehrlich and RL31 ascites tumours when
they were treated with both 500 and 50pugkg-' of
SSM. However, when tumour-bearing normal mice
were treated i.p. with 5upgkg-1 of SSM or 0.5ml of
saline, all died. In addition, when nu/+ mice
bearing tumours received 500pgkg-1 of SSM, the
antitumour effect was equivalent to that observed in
normal mice (Table Ib). The antitumour activity of
SSM was, therefore, detectable in this experimental
tumour model and the following experiments were
performed utilizing the two groups of immuno-
compromised mice. As shown in Table Ic, a
significant protective effect was noted in tumour-
bearing mice treated with anti-mouse IFNy anti-
serum and 500 or 50pgkg-1 of SSM as compared
to those treated with saline. In T cell deficient
(nu/nu) mice, however, no protective effect of SSM
was observed possibly due to a deficit in
supressor/cytotoxic Ly-2,3+ T cells, which also
produce IFNy (Sonnenfeld et al., 1979). As the
tumour-bearing nu/nu mice had no inhibition of
tumour growth following SSM administration,
functional T cells, but not IFNy induction,
appeared to be required for the antitumour effect.
In order to determine if serum IFN levels played a
role during the treatment course with SSM, sera
were obtained from all groups after each SSM
administration and assayed for IFN activity. After
several treatments with SSM, no serum IFN
activity was detected in any of the groups (data not
shown).
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Since various IFNs have been reported to exhibit
antitumour activity in vivo and in vitro (Sikora et
al., 1983), the antitumour activity associated with
IFN inducers (or immunopotentiators) appears to
be dependent upon the induction of IFN. The
present study suggests that the antitumour activity
of SSM may not be related to the induction of
circulating IFN. However, T cells appear to be
required since tumour-bearing T cell deficient mice
(nu/nu mice) did not reveal a tumour inhibitory
effect after SSM administration. SSM had no direct
cytoxicity against cancer cells in vitro (Kimoto et
al., 1982), and cells considered to be possible
effectors in antitumour activity including NK cells,
CTL, and activated MO have been reported to be
stimulated by SSM. These observations suggest that
the antitumour effect of SSM are mediated by more
than one mechanism. The data described here
indicate that circulating IFNy induction by SSM
may not be related to its suppression of tumours
inoculated in mice.
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